Medicinova Inc (OQ:MNOV)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: SUITE 650, 4275 EXECUTIVE SQUARE
LA JOLLA CA 92037
Tel: N/A
Website: https://medicinova.com
IR: See website
<
Key People
Yuichi Iwaki
President, Chief Executive Officer, Director
Jason J. Kruger
Chief Financial Officer
Kazuko Matsuda
Chief Medical Officer, Director
David H. Crean
Chief Business Officer
   
Business Overview
MediciNova, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States market. It is focused on its development activities on MN-166 (ibudilast) for neurological and other disorders, such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (e.g., methamphetamine dependence, opioid dependence, and alcohol dependence), prevention of acute respiratory distress syndrome (ARDS), and Long COVID, and MN-001 (tipelukast) for fibrotic and other diseases, such as nonalcoholic fatty liver disease (NAFLD) and idiopathic pulmonary fibrosis (IPF). The Company's pipeline also includes MN-221 (bedoradrine) for the treatment of acute exacerbation of asthma and MN-029 (denibulin) for solid tumor cancers.
Financial Overview
For the fiscal year ended 31 December 2023, Medicinova Inc revenues increased from $0K to $1M. Net loss decreased 39% to $8.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development and patents decrease of 39% to $5.4M (expense), Interest Income increase from $810K to $1.8M (income), General decrease of 9% to $4.4M (expense).
Employees: 13 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $15.46M as of Dec 31, 2023
Annual revenue (TTM): $1.00M as of Dec 31, 2023
EBITDA (TTM): -$9.88M as of Dec 31, 2023
Net annual income (TTM): -$8.57M as of Dec 31, 2023
Free cash flow (TTM): -$7.43M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 49,046,246 as of Feb 12, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.